The European Group for the Study of Insulin Resistance (EGIR) has compiled large numbers of biological samples from studies conducted at 19 clinical research centers across Europe as part of their effort to understand insulin resistance and how it affects disease. Metabolon will discover and validate the biomarkers found in these samples that relate to insulin resistance. These markers will be used to help further develop Metabolon’s diagnostic test for pre-diabetic patients.
John Ryals, president and CEO of Metabolon, said: “This collaboration with EGIR will help Metabolon accelerate the development of Quantose IR, our diagnostic test for better screening of pre-diabetic patients. This routine test will help identify pre-diabetic patients years before they become diabetic. With this information in hand, doctors can intervene with lifestyle or drug therapies which may delay or prevent the onset of type 2 diabetes.”